Constitutively activated pathways contribute to apoptosis resistance in chronic lymphocytic leukemia (CLL). Little is known about the metabolism of lipids and function of lipases in CLL cells. Performing gene expression profiling including B-cell receptor (BCR) stimulation of CLL cells in comparison to healthy donor CD5 þ B cells, we found significant overexpression of lipases and phospholipases in CLL cells. In addition, we observed that the recently defined prognostic factor lipoprotein lipase (LPL) is induced by stimulation of BCR in CLL cells but not in CD5 þ normal B cells. CLL cellular lysates exhibited significantly higher lipase activity compared to healthy donor controls. Incubation of primary CLL cells (n ¼ 26) with the lipase inhibitor orlistat resulted in induction of apoptosis, with a halfmaximal dose (IC 50 ) of 2.35 lM. In healthy B cells a significantly higher mean IC 50 of 148.5 lM of orlistat was observed, while no apoptosis was induced in healthy peripheral blood mononuclear cells (PBMCs; Po0.001). Orlistat-mediated cytotoxicity was decreased by BCR stimulation. Finally, the cytotoxic effects of orlistat on primary CLL cells were enhanced by the simultaneous incubation with fludarabine (P ¼ 0.003). In summary, alterations of lipid metabolism are involved in CLL pathogenesis and might represent a novel therapeutic target in CLL.
Introduction
B-cell chronic lymphocytic leukemia (B-CLL) is the most common leukemic disorder in the western hemisphere. It is characterized by an accumulation of mature B cells in the blood, bone marrow and secondary lymphoid organs. 1 The accumulation of the malignant cells is caused not only by dysregulation of apoptosis but also by a dynamic proliferation. 2 A major factor in the pathogenesis of CLL is the microenvironment of the leukemic cell, 3 especially the role of antigenic stimulation via the B-cell receptor (BCR). 4 An unmutated status of the IgV H gene was shown to exhibit enhanced autoreactivity 5 and to predict an unfavorable prognosis in CLL. 6 Furthermore, expression of ZAP-70 is associated with an enhanced signal transduction via the BCR complex. 7 Based on the central relevance of BCR-signaling in CLL, we applied gene expression profiling of primary CLL cells including the analysis of BCR stimulation. Lipase activity was identified as a prominent pathway in CLL cells and the recently identified prognostic factor lipoprotein lipase (LPL) was seen to be specifically induced by stimulation of the BCR. 8, 9 LPL is a secreted enzyme, acts at the vascular side of endothelium and plays a central role for energy supply from serum triglycerides in peripheral tissues. 10 Here, we found that the lipase inhibitor orlistat, known as an effective inhibitor of LPL, acts as a cytotoxic agent in CLL cells by its proapoptotic effects. 11 
Materials and methods

Patients and cells
After informed consent, blood was obtained from patients fulfilling diagnostic criteria for B-CLL. Only patients without prior therapy or at least 6 months without prior chemotherapy were included in this study. Fresh B-CLL samples were enriched by applying B-RosetteSep (Stem Cell Technologies, Vancouver, BC, Canada) and Ficoll-Hypaque (Seromed, Berlin, Germany) density gradient purification resulting in purity of 498% of CD19 þ /CD5 þ B-CLL cells. CLL cells were characterized for CD19, CD5, CD23, FMC7, CD38, ZAP70, sIgM, sIgG, CD79a and CD79b expression on a FACS Canto flow cytometer (BD PharMingen, Heidelberg, Germany). IgV H -hypermutational status of CLL patients was analyzed as previously published. 12 Controls were isolated from healthy blood donors using anti-CD19-MACS-beads (Miltenyi, Bergisch-Gladbach, Germany) and subsequent positive selection with CD5-PE (BD PharMingen) and anti-PE-Beads (Miltenyi) resulting in at least 80% CD19 þ / CD5 þ B cells. This study was approved by the ethics committee of the University of Cologne (Approval No. 01-163, 9 October 2001), blood samples were given with informed consent according to the Helsinki protocol.
Real-time PCR Quantitative PCR. Quantification of LPL mRNA was performed by LightCycler Taqman Master (Roche, Penzberg, Germany). Universal probe No. 13 (Roche) with forward primer GCCCAGCTACAACCACCA and reverse primer TGTGAGCCA TAGTCCAGTGC was used for LPL amplification. b-2-Microglobulin was applied as housekeeping gene standard by Universal probe No. 42 (Roche) with forward primer TTCTGGCCTGGAGGCTATC and Reverse Primer TCAGGAAA TTTGACTTTCCATTC. All experiments were performed in replicates and crossing points were determined by second derivative maximum method. Relative quantification analysis was performed by Exxor3 software package (Roche).
Stimulation of cells
Cells were cultivated in IMDM (Invitrogen, Carlsbad, CA, USA) supplemented with 10% heat-inactivated fetal calf serum (FCS), 2 mM L-glutamine, 100 U ml À1 penicillin and 100 mg ml À1 streptomycin, and incubated at 37 1C in a 5% CO 2 humidified atmosphere. BCR stimulation was performed as previously described. Briefly, anti-IgM-polyacrylamid Immunobead reagent (Irvine Scientific, Santa Ana, CA, USA) was added to isolated B-CLL cells and incubated for 3 h. 13 Anti-IgA-immunobeads served as additional negative control.
Gene expression profiling
High-quality total RNA was extracted by Trizol (Invitrogen) lysis and subsequent RNA-clean-up (Qiagen, Hilden, Germany). Total RNA (100 ng) was used for reverse transcription, second strand synthesis and in vitro transcription for generation of biotinylated cRNA according to the manufacturers' protocols. For gene expression analysis Illumina WG6 Bead Chip Arrays (Illumina, San Diego, CA, USA) containing 447 000 transcripts were hybridized, scanned and decoded as previously described. 14 
Treatment of cells
Orlistat (Sigma, Steinheim, Germany) was dissolved in dimethyl sulfoxide (DMSO) and applied for CLL inhibition using 1-100 mM concentrations. Fludarabine (Schering, Berlin, Germany) was dissolved in water and applied in 10 mM concentration. DMSO-treated cells were taken as baseline control; effective DMSO concentration in all treatments was 0.1%.
Lipase activity assay
Lipase activity of cellular LPL was assessed by using Confluolip fluorimetric lipase activity assay (Progen, Heidelberg, Germany) according to the manufacturers' protocol. Briefly, CLL cells and peripheral blood mononuclear cells (PBMC) were cultured for 24 h, washed and lysed using Triton X-100. For analysis of lipase activity, 100 mg of cellular lysate was added to 1-trinitrophenylaminododecanoyl-2-pyrendecanoyl-3-0-hexadecyl-sn-glycerol as substrate solution kept at 37 1C. Fluorescence of quenched pyrene, after adding lipase containing samples, was measured in a kinetic assay using 342 nm excitation and 400 nm emission in a thermostated cuvette at 37 1C. Purified LPL (Sigma) served as positive control. Serial dilutions of fluorescence standard were used for calibration of measurement of cellular lysates and positive control.
Apoptosis and cell viability
Apoptosis was determined by flow cytometry using Annexin V-FITC/7AAD staining (BD PharMingen). Cell viability was additionally analyzed using XTT assays with cell proliferation Kit II (Roche). Analysis for poly(ADP-ribose) polymerase (PARP) cleavage was done by applying equal amounts of cells for lysis and western blotting; anti-PARP (NEB, Ipswich, MA, USA) was used for detection of PARP cleavage.
Curve fitting was performed using SIGMAPLOT (SPSS Inc., Chicago, IL, USA). IC 50 values were determined by fitting data to the Hill's equation, that is,
Statistical analysis of gene expression data
The log2 expression values of the Illumina Whole Genome Bead Chip Array data were used in this analysis. In order to compare the data from different arrays, a z-transformation was applied to each array. The parameters of the z-transformation were chosen in such a way that the distribution of transcripts that were not expressed (unexpressed genes) is mapped to a standard normal distribution (unit transformation). The distribution of the expressed genes (z41) was analyzed to be log normal distributed. This distribution could be normalized by a log transformation. Ward's hierarchical clustering algorithm was used with correlation distance between CLL samples and controls ( Figure 1a) . The same distance measure was used in multidimensional scaling (MDS). MDS was applied to project the distances of the 78 genes into a two dimensional space (Figure 1b) . Robust mean and variance are calculated for a two-group t-statistic. This statistic was used to identify differentially expressed genes (Figure 1c) .
Results
Lipases and lipase activity associated genes are overexpressed in B-CLL patients B cells. After purification, cells were incubated for 3 h with anti-human IgM-immunobead reagent for BCR stimulation, with anti-human IgA-immunobeads as negative control, or remained untreated in culture medium. Total RNA was extracted from both BCR-stimulated and BCR-unstimulated samples and applied to the Illumina Whole Genome Bead Chip Array containing 447 000 transcripts. The anti-IgA control revealed similar gene expression profiles as untreated negative controls. Subsequent analysis of gene expression profiles revealed significant changes in lipid metabolism associated genes when comparing CLL cases with healthy controls. Further analysis based on the Gene Ontology (GO) database AmigO revealed 78 genes defined by the GO-term 'lipase activity' as discriminator of healthy donor samples and diseased CLL samples. Hierarchical clustering and MDS analysis showed that 78 genes exhibiting lipase activity or bearing a close relation to lipase activity clearly define the healthy and the diseased subset (Figures 1a and b) . A total of 21 of 78 genes according to the lipase activity GO-term were identified to be the principle components of differential expression. Of these 21 differentially expressed genes, 20 were overexpressed in CLL ( Figure 1c) .
The majority of genes in this cluster exhibited phospholipase activity. Most prominently, seven of these genes were phospholipase A2 (PLA2) enzymes or showed PLA2 domain homologies. PLA2 g (PLA2G4C), group IIF phospholipase (PLA2G2F) and group IIE phospholipase (PLA2G2E) induce the release of arachidonate from phospholipids. [15] [16] [17] LEP14 and LEP13 18 were predicted in silico to have PLA2 activity, and PATE bears a putative PLA2 motif. 19 Adiponutrin is similar to patatin-like phospholipase domain-containing protein 3 and also shows PLA2 activity. 20 Phospholipase C activity or relation was found in five genes; phospholipase C-b (PLCb1) catalyzes the generation of inositol 1,4,5-trisphosphate and diacylglycerol from phosphatidylinositol 4,5-bisphosphate, a key step in the intracellular transduction of many extracellular signals, 21 whereas PLC-b2 prefers phosphatidyl-inositol 4,5-bisphosphate to phosphatidylinositol as substrate. 22 The bradykinin receptor B2 is directly interacting with phospholipase C and provides mitogenic stimuli. 23, 24 Two genes associated with phospholipase D activity were also identified: first phospholipase D2 (PLD2) catalyzes the hydrolysis of PC to produce phosphatidic acid and choline, PLD2 was shown to prevent apoptosis in cancer cell lines 25, 26 and increases Syk-mediated signaling in mast cells. 27 We also identified LPL as CLL-specific expressed gene in agreement with previously published data. 8, 28 As expected, LPL expression was found in samples from unstimulated IgV H -unmutated CLL patients, but not from healthy donor cells or BCR-unstimulated IgVH-mutated patients.
Cellular lipase activity in CLL and healthy donor cells
For detection of intracellular and cellular bound lipases, a total lipase activity assay was performed using 1-trinitrophenylaminododecanoyl-2-pyrendecanoyl-3-0-hexadecyl-sn-glycerol as substrate for triglyceride specific hydrolysis by cellular lysates of CLL (n ¼ 6) and healthy donor control B-cells and PBMC (n ¼ 4). Fluorimetric kinetic measurement of cellular lysates including purified LPL þ control revealed activity of both hepatic and LPL, a pH of 8.2 allowed analysis of LPL activity as main part of total lipase activity ( Figure 2) .
Comparison of lipase activity in CLL-cell lysates revealed an activity of 1248.3 U mg À1 while healthy donor PBMC showed significantly lower lipase activity of 72 U mg À1 as shown in 
BCR stimulation significantly increases LPL expression in B-CLL cells
Gene expression profiling further indicated that LPL expression was specifically induced by BCR stimulation in CLL cells. No expression was seen in healthy donor control CD5 þ B cells after BCR stimulation. To verify the expression data, we performed real-time PCR for quantitative analysis of LPL. In CD5 þ healthy donor B cells (n ¼ 9), no significant expression of LPL could be detected either in unstimulated (median expression ratio (ER) 0.3) or in BCR-stimulated cells (mean ER 0.58; P40.05). In CLL cells (n ¼ 28) a significant increase of LPL expression was observed after BCR stimulation (median ER 0.21 versus 14.59; Po0.01). When separating IgV H -mutated andunmutated CLL samples, induction of LPL was seen in both subsets. In IgV H -unmutated samples (n ¼ 11) we found a 4.75-fold increase after BCR stimulation (median ER 3.2 versus 15.23, Po0.05). In IgV H -mutated samples (n ¼ 17) unstimulated cells exhibited low LPL expression (median ER ¼ 0.08). Nevertheless, after BCR stimulation LPL expression was induced (median ER ¼ 0.08 versus 7.87, Po0.01) (Figure 3) .
Effects of orlistat treatment in primary CLL samples
Among the genes associated with lipase activity, LPL was a particularly interesting candidate gene. First, it has been shown recently that this gene might serve as a surrogate marker for unfavorable prognosis in CLL. Second, the overexpression of LPL and its regulation by BCR stimulation in CLL allowed to hypothesize that this protein might not only serve as a surrogate marker but might also be involved in the pathophysiology of CLL. Third, as shown above, CLL cells exhibit significantly higher lipase activity compared to healthy donor controls (Figure 3) . Moreover, LPL can be targeted with the specific lipase inhibitor orlistat (tetrahydrolipstatin).
To address the potential role of LPL, we tested the effects of a lipase inhibitor, orlistat (tetrahydrolipstatin), which has a rather broad specificity for lipases and is approved for the treatment of obesity. When assessing cell survival of B-CLL cells exposed to 
À1
; P ¼ 0.0021; left box). Orlistat treatment significantly reduces lipase activity in CLL cell lysates (P ¼ 0.0062; right box) while no effect could be seen for control cells (data not shown).
increasing concentrations of orlistat, a specific and concentration-dependent induction of apoptosis and cell death in primary CLL cells was observed.
Freshly isolated CLL cells (n ¼ 12) were incubated with increasing concentrations of orlistat (1-100 mM). The influence on cell viability was measured by XTT assay. The induction of apoptosis was analyzed by Annexin V/7-AAD flow cytometry. Annexin V/7-AADÀ cells were defined as viable cells and background apoptosis rates were subtracted for determination of IC 50 . With this method, the half-maximal inhibitory concentration (IC 50 ) of orlistat was determined at 2.35 mM after 24 h incubation (after 48 h at 1.58 mM). A similar IC 50 value of 5.48 mM of orlistat was found by the XTT cytotoxicity assay. In healthy donor B cells (n ¼ 6), orlistat showed a significantly higher IC 50 of 148.5 mM. On healthy donor PBMCs without prior cell sorting, 100 mM orlistat induced only marginal apoptotic effects with 13.1% Annexin V þ cells (Figure 4a) .
We further investigated the impact of LPL expression, clinical stage, IgV H -mutational status and ZAP70 expression on sensitivity of CLL cells toward orlistat. Suboptimal doses of 20 mM orlistat incubated with CLL cells for 24 and 48 h were used. After 24 h, LPLÀ patients (n ¼ 8) showed 40.8% viable cells while LPL þ cells (n ¼ 6) showed no significant difference with 41.5% viability (P ¼ 0.9). After 48 h, LPLÀ patients showed 22.1% viability, in LPL þ a reduced viability of 14.2% was seen. Nevertheless, no significant difference could be demonstrated (P ¼ 0.12) indicating no significant susceptibility toward orlistat in the LPL-defined patient subgroups (Figure 4b ). Samples derived from patients in clinical stage Binet A (n ¼ 6) showed 68.5% apoptosis, those from Binet B stage patients (n ¼ 7) 66.0% and Binet C stage patients (n ¼ 8) 55.0% apoptosis, indicating that there was no significant difference shown in orlistat response with regard to Binet stage. Analyzing the correlation of the response to orlistat with the ZAP70 expression, 20 mM orlistat (for 24 h) induced a 63.7% apoptosis induction in ZAP70À patients (n ¼ 16) and 55.7% apoptosis induction in ZAP70 þ patients (n ¼ 7) (P ¼ n.s.). The comparison for IgV Hmutational status did also not reveal any significant difference. Sensitivity toward orlistat treatment of three patients harboring 17 deletion were analyzed revealing individual IC 50 values of 5, 10 and 8.5 mM, indicating susceptibility to orlistat treatment in the p53 deleted subgroup.
The induction of apoptosis was additionally examined by detection of cleaved PARP in orlistat-treated cells. Orlistat treatment caused a dose-dependent effect on PARP with a total cleavage of the 116 kDa isoform to the 89 kDa cleaved PARP at 100 mM orlistat in all three CLL samples analyzed. No specific cleavage of PARP was detected using PBMCs derived from healthy donors (Figure 4c) .
The proapoptotic effects of orlistat treatment in CLL cells was further analyzed by caspase inhibition with the pan-caspase inhibitor z-VAD. CLL cells (n ¼ 5) were incubated with 20 mM orlistat and 20 mM z-VAD pan-caspase inhibitor for 48 h. Caspase inhibition by z-VAD in 20 mM orlistat-treated CLL cells revealed significantly enhanced viability of 42 versus 9.9% in solely 20 mM orlistat-treated CLL cells (P ¼ 0.016) (Figure 4d) .
Again, for detection of intracellular and cellular bound lipases, a total lipase activity assay applied to cellular lysates of CLL cells (n ¼ 6) was treated with orlistat ( Figure 2) . Incubation of CLL cells with orlistat revealed dose-dependent decrease of lipase activity to 721.9 U mg À1 by 5 mM orlistat treatment (P ¼ n.s.) and significantly decreased to 617 U mg À1 by 20 mM orlistat treatment (P ¼ 0.0062) (Figure 2) .
To assess the relevance of triglyceride catalysis and accessibility of free fatty acids for survival of CLL cells we substituted 15 mM palmitic acid solved in DMSO to orlistat-treated CLL cells (n ¼ 6) and healthy donor controls (n ¼ 4) (Figure 5a ). Addition of palmitic acid revealed a partly reduced cytotoxicity of lowdose orlistat (1 mM) in CLL cells (P ¼ 0.02), whereas no significant effect could be observed in healthy donor B cells. Nevertheless, a complete depletion of orlistat toxicity could not be achieved by palmitic acid substitution.
As shown above, various target genes can be postulated as mediators of specific orlistat toxicity in CLL cells. Fatty acid synthase was previously published as orlistat target. Fatty acid synthase inhibitor C75 (Alexis) was used for further elucidation of underlying pathways of CLL orlistat susceptibility (Figure 5b ). We assessed C75 as a selective fatty acid synthase inhibitor for toxicity assays in CLL patients (n ¼ 4) and healthy donor B cells (n ¼ 4). In CLL patient cells, IC 50 of C75 treatment was determined for 20.03 mM, in healthy donors a slightly increased IC 50 of 44.82 mM was observed (P ¼ 0.0059).
Since LPL is induced by BCR stimulation, we analyzed the influence of BCR stimulation on orlistat sensitivity. BCRunstimulated and BCR-stimulated CLL cells were treated with 20 and 100 mM orlistat, cell viability was assessed by Annexin V/ 7-AAD flow cytometry and was compared to DMSO control. After BCR stimulation, the induction of apoptosis by orlistat was partially inhibited; at 20 mM orlistat the rate of viable cells was 24.2% in unstimulated cells and 44.2% in BCR-stimulated CLL cells (n ¼ 18; Po0.001). Using 100 mM orlistat, the rate of viable cells was 13.9% in unstimulated cells versus 37.2% in BCRstimulated CLL cells (n ¼ 18; P ¼ 0.001) (Figure 5c ).
When combined with fludarabine, orlistat showed additive cytotoxic effects on CLL cells (n ¼ 6). Submaximal doses of 10 mM fludarabine and of 20 mM orlistat yielded an induction of apoptosis in 32.0 and 66% of CLL cells, respectively. The combination of 10 mM fludarabine and 20 mM orlistat induced the apoptosis in 80.5% of CLL cells, which was superior compared to orlistat alone (P ¼ 0.03) (Figures 6a and b) .
Discussion
The application of gene expression analysis on CLL cells compared to CD5 þ B cells as their physiological counterpart led to the identification of a gene cluster defined by the GO-term 'lipase activity', 29 reliably distinguishing between both subsets. Gene expression of 78 lipases and lipase activity associated genes was demonstrated as significant difference between healthy and malignant B cells. To pursue the gene expression-based findings of lipase activity as CLL-specific feature we performed functional assessment of lipase activity exhibited by CLL cells in comparison to healthy donor controls. Triglyceride-specific lipase activity could be significantly increased in CLL cells compared to healthy donor controls. Here we could link descriptive microarray data to enzymatic function to propose lipid metabolism as functional relevant feature in CLL. This suggests that the role of lipid metabolism might have been underestimated in B-CLL in the past. Principle component analysis of our microarray data set revealed 21 genes to be the major constituents in definition of functional difference between healthy B cells and CLL. Seven of these genes were identified as members of the PLA2 family. PLA2 cytoplasmatic level correlates with apoptosis 30 and PLA2 is important for maintaining the phospholipids composition of the membrane especially during oxidative stress. 31 Another interesting link between apoptosis and lipid metabolisms originates from studies on PLD2, which we also identified as upregulated in B-CLL cells. In fact, PLD2 was shown to prevent apoptosis in cancer cell lines 25, 26 and increases Syk-mediated signaling in mast cells. 27 Similarly, PLC is an important enzyme in intracellular signaling and was recently identified to be involved in CLL BCR signaling. 32 Here we identified five PLC genes overexpressed in CLL indicating the activation of this pathway in CLL.
It was recently shown that LPL expression in CLL is associated with unmutated IgV H -hypermutational status, 8, 28, 33, 34 providing better predictive value compared to ZAP70 expression. 2 Our study adds to this knowledge by showing that LPL as a recently identified prognostic marker in CLL is induced by BCR stimulation. This indicates that pathways of the lipid metabolism might be critically involved in CLL pathogenesis. We could show that LPL is regulated by BCR stimulation in vitro in both IgV H -mutated and IgV H -unmutated CLL patient cells.
Recently, IgV H -unmutated CLL cells were demonstrated to exhibit autoreactive BCR reactivity. 5 Two lines of evidence suggest that LPL might indeed be regulated by BCR activation in vivo: first, LPL expression in vivo is almost exclusively seen in IgV H -unmutated CLL, which are associated with autoreactive BCR activity;
5 second, we demonstrate here that LPL is induced or significantly increased by BCR stimulation ex vivo. Therefore, LPL expression has to be determined as a prerequisite feature of CLL cells.
The functional role of the cytoplasmatic expression of LPL in CLL cells remains unclear, since LPL is a secreted enzyme, acts at the vascular side of endothelium and plays a central role for energy supply from serum triglycerides in peripheral tissues. 10 The relation of LPL to BCR stimulation suggests a central role in CLL pathogenesis and supports the hypothesis of a persistent autoreactive BCR stimulation of IgVH-unmutated CLL cells in the microenvironment of the malignant cell. This CLL-specific expression pattern elucidates LPL as a potential therapeutic target.
The identification of numerous lipase activity exhibiting genes in CLL led us to screen for putative drugs that act by inhibition of lipases. Orlistat is a broadly applied drug in obesity treatment inhibiting gastro-intestinal lipases. 35 It shows a broad activity against, for example, gastric and pancreatic lipases. Only recently, orlistat was identified as an effective inhibitor of LPL, 11 phospholipases 36 and PLA2. 37 Applying the clinically used lipase inhibitor to study the potential role of LPL in B-CLL we obtained a rather surprising result. Orlistat effectively induced apoptosis in CLL cells with an IC 50 of 2.35 mM, while PBMC were basically not affected and the IC 50 for purified B cells from healthy donors was almost two magnitudes higher. Orlistat has been described to inhibit prostate cancer cell lines by inhibiting fatty acid synthase, 38 similar effects have been observed in breast cancer cell lines. 39 These effects have been mainly attributed to the overexpression of fatty acid synthase in these cancer cell lines. 40 Based on our expression data, no significant expression of fatty acid synthase in CLL was seen. In addition, we targeted fatty acid synthase by the FAS-specific inhibitor C75. High dosage of half-maximal 20 mM is necessary to induce cytotoxicity. In healthy donor controls a significantly increased IC 50 of 44.82 mM was observed. Nevertheless, high dosage of C75 is necessary and comparable amounts induce apoptosis in healthy donor cells as well. Fatty acid synthase might by free fatty acid supply in part contribute to CLL cell survival.
To reveal further insight in orlistat cytotoxicity we performed substitution of palmitic acid as free fatty acid during orlistat. This resulted in a significant reduction of orlistat cytotoxicity. A complete termination of orlistat effects could not be achieved, indicating that energy supply through fatty acid may in part play a role in exhibiting orlistat cytotoxicity. In addition, orlistat seems to exert apoptosis induction in a caspase-dependent manner, as shown by countering orlistat toxicity with z-VAD pan-caspase inhibitor.
Several mechanisms of orlistat cytotoxicity in CLL cells can be hypothesized from our data. First, orlistat can decrease energy sources of the CLL cell by inhibition of LPL. Second, the disruption of intracellular phospholipase-dependent mediator pathways can influence survival signals of the CLL cell. Third, membrane stability can be decreased by blocking PLA2 activity.
Here we could identify the availability of free fatty acid as at least one component of orlistat toxicity. This finding is supported by functional lipase activity analysis in orlistat-treated CLL cells, harboring a decreased triglyceride specific lipase activity by orlistat treatment. A miscellaneous mechanism might be the basis for induction of apoptosis by the broad-spectrum lipase inhibitor orlistat specifically in CLL and future studies have to further elucidate the metabolic changes induced by orlistat.
We compared orlistat to fludarabine as a well-established and potent drug in CLL treatment 41 and found additive cytotoxic effects in combining orlistat with fludarabine. Fludarabine acts as an antimetabolite in nucleoside metabolism, 42 and so far no interference with lipid metabolism was reported. In oral application as anti-obesity treatment, orlistat shows little side effects. Overdosage in humans with increased systemic uptake did not reveal severe side effects 43 and animal models with extreme overdosage did not reveal cytotoxic effects of orlistat either (FDA hearing protocol).
These novel findings allow to speculate that drugs targeting the lipid metabolism might be a new class of agents for the treatment of CLL. Future investigations should aim at investigating these agents in animal models.
